Zacks Investment Research upgraded Teleflex Incorporated (NYSE:TFX) to Hold in a report released today.
- Updated: November 26, 2016
Zacks Investment Research has upgraded Teleflex Incorporated (NYSE:TFX) to Hold in a report released on 11/26/2016.
On 2/26/2016, Leerink Swann released a statement about Teleflex Incorporated (NYSE:TFX) bumped up the target price from $143.00 to $153.00 that suggested an upside of 0.06%.
Boasting a price of $153.19, Teleflex Incorporated (NYSE:TFX) traded 1.25% higher on the day. With the last close down -9.50% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. The company has recorded a 50-day moving average of $154.04 and a 200-day moving average of $169.28. 214,848 shares of TFX traded hands, down from an average trading volume of 355,889
Recent Performance Chart
Teleflex Incorporated has 52 week low of $125.28 and a 52 week high of $188.79 with a P/E ratio of 26.46 and has a market cap of $0.
Also covering Teleflex Incorporated's price target, a total of 11 brokerages have released a ratings update on TFX. The one year target is $167.36 with four equity analysts rating the stock a strong buy, 5 brokers rating the stock a buy, 3 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Teleflex Incorporated (NYSE:TFX)
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company manufactures its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company's all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.